Pfizer (Biosimilars Infliximab Portfolio) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Pfizer (Biosimilars Infliximab Portfolio) General Information

Description

European Rights of Remicade biosimilar products. The asset is the rights to develop and manufacture the product, infliximab (PF-06438179), which is a tumor necrosis factor alpha (TNF-alpha) inhibitor designed to treat a range of autoimmune diseases, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and plaque psoriasis.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Sandoz International
Primary Office
  • 235 East 42nd Street
  • New York, NY 10017
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Pfizer (Biosimilars Infliximab Portfolio) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pfizer (Biosimilars Infliximab Portfolio)‘s full profile, request access.

Request a free trial

Pfizer (Biosimilars Infliximab Portfolio) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pfizer (Biosimilars Infliximab Portfolio)‘s full profile, request access.

Request a free trial